NBSE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBSE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
NeuBase Therapeutics's Total Assets for the quarter that ended in Sep. 2023 was $18.62 Mil.
During the past 12 months, NeuBase Therapeutics's average Total Assets Growth Rate was -36.60% per year.
During the past 13 years, NeuBase Therapeutics's highest 3-Year average Total Assets Growth Rate was 276.40%. The lowest was -75.50%. And the median was -1.80%.
Total Assets is connected with ROA %. NeuBase Therapeutics's annualized ROA % for the quarter that ended in Sep. 2023 was -35.57%. Total Assets is also linked to Revenue through Asset Turnover. NeuBase Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.
The historical data trend for NeuBase Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuBase Therapeutics Annual Data | |||||||||||||||||||||
Trend | Sep12 | Sep13 | Sep14 | Sep15 | Sep16 | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | |||||||||||
Total Assets | Get a 7-Day Free Trial | 27.93 | 0.25 | 12.53 | 34.44 | 64.17 |
NeuBase Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Total Assets | Get a 7-Day Free Trial | 32.69 | 25.58 | 21.46 | 22.33 | 18.62 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
NeuBase Therapeutics's Total Assets for the fiscal year that ended in Sep. 2021 is calculated as
Total Assets | = | Total Equity (A: Sep. 2021 ) | + | Total Liabilities (A: Sep. 2021 ) |
= | 54.07 | + | 10.098 | |
= | 64.17 |
NeuBase Therapeutics's Total Assets for the quarter that ended in Sep. 2023 is calculated as
Total Assets | = | Total Equity (Q: Sep. 2023 ) | + | Total Liabilities (Q: Sep. 2023 ) |
= | 9.137 | + | 9.485 | |
= | 18.62 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuBase Therapeutics (NAS:NBSE) Total Assets Explanation
Total Assets is connected with ROA %.
NeuBase Therapeutics's annualized ROA % for the quarter that ended in Sep. 2023 is
ROA % | = | Net Income (Q: Sep. 2023 ) | / | ( (Total Assets (Q: Jun. 2023 ) | + | Total Assets (Q: Sep. 2023 )) | / count ) |
= | -7.284 | / | ( (22.334 | + | 18.621) | / 2 ) | |
= | -7.284 | / | 20.4775 | ||||
= | -35.57 % |
Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
NeuBase Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 is
Asset Turnover | ||||||
= | Revenue (Q: Sep. 2023 ) | / | ( (Total Assets (Q: Jun. 2023 ) | + | Total Assets (Q: Sep. 2023 )) | / count ) |
= | 0 | / | ( (22.334 | + | 18.621) | / 2 ) |
= | 0 | / | 20.4775 | |||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of NeuBase Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Symetryx Corp | 10 percent owner | 2828 BATHURST ST #400, TORONTO A6 M6B3A7 |
Aleta Shiff | 10 percent owner | 461 LYTTON BLVD., TORONTO A6 M5N 1S5 |
Barry Shiff | 10 percent owner | 461 LYTTON BLVD., TORONTO A6 M5N 1S5 |
William Roland Mann | officer: COO | 700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219 |
Todd P. Branning | officer: Chief Financial Officer | C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Eric I Richman | director | C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854 |
Eric J Ende | director | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
Sandra Rojas-caro | officer: Chief Medical Officer | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746 |
Kianoush Motesharei | officer: See Remarks | 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219 |
Gerald J Mcdougall | director | 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219 |
Curt Bradshaw | officer: Chief Scientific Officer | 177 E COLORADO BLVD, STE 700, PASADENA CA 91105 |
Gines Diego Miralles | director | 2235 VIA FRESCA, LA JOLLA CA 92037 |
Franklyn G Prendergast | director | |
Dietrich A Stephan | director, 10 percent owner, officer: President and CEO | 213 SMITHFIELD ST, PITTSBURGH PA 15222 |
Lipizzaner Llc | 10 percent owner | 1209 ORANGE STREET, WILMINGTON DE 19801 |
From GuruFocus
By Marketwired • 06-30-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By sperokesalga sperokesalga • 05-24-2023
By PurpleRose PurpleRose • 08-11-2022
By Marketwired • 06-28-2023
By GuruFocusNews GuruFocusNews • 07-01-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By Marketwired • 06-29-2023
By Value_Insider Value_Insider • 10-21-2022
By sperokesalga sperokesalga • 05-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.